Ceftolozane-tazobactam pharmacokinetics during extracorporeal membrane oxygenation (ECMO) 23 has not been previously studied. In this work we report on the ceftolozane and tazobactam 24 plasmatic levels in a lung transplant recipient during ECMO, treated with ceftolozane-tazobactam 25 (2g/1g, intravenously every 8 h, 1 h infusion) for a Pseudomonas aeruginosa pulmonary infection.
3
Ceftolozane-tazobactam (Merck Sharp & Dohme Corp. NJ, USA) is a recently introduced -lactam 31 plus -lactamase inhibitor combination targeting Gram-negative pathogens, including multi-drug 32 resistant (MDR) Enterobacterales and Pseudomonas aeruginosa, with the exclusion of 33 carbapenemase-producing strains. At the registered dose of 1.5 g (1 g/0.5 g) every 8 hours, 34 ceftolozane-tazobactam is currently approved for the therapy of complicated urinary tract and intra- 35 abdominal infections (in the latter case in association with metronidazole). (1, 2) Ceftolozane-36 tazobactam has been successfully used for treatment of lower respiratory tract infections (LRTI) 37 caused by MDR P. aeruginosa, also in cystic fibrosis patients. (3-5) Results of a phase 3 safety and 38 efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (MK-7625A-39 008) will be available in the next future.
40
The PK/PD index of ceftolozane that best correlates with in vivo efficacy is the percentage of the 
71
The tracheal aspirate culture, performed on day 2 after admission, grew a carbapenem-resistant P. 72 aeruginosa (Table 1) , Based on susceptibility testing results, the antimicrobial therapy was 73 modified to vancomycin, amikacin and ciprofloxacin. However, the culture of the tracheal aspirate, 74 performed on hospital day 10, was still positive for P. aeruginosa >1 x 10 6 CFU/mL with an 75 identical antimicrobial susceptibility profile.
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On hospital day 13 the patient was subjected to bilateral lung transplantation. During surgery, the 77 extracorporeal support was switched from veno-venous to veno-arterial (vaECMO) and then 78 maintained for hemodynamic instability. 
